Remdesivir delivers another perverse result
The antiviral is just about positive in a moderate Covid-19 study, but paradoxically only as a limited regimen.
Asco 2020 – Enhertu impresses, but can it live up to high hopes?
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
Ibrance trial halt threatens Pfizer’s growth targets
One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
Asco 2020 – J&J sees multiple myeloma responses deepen
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
Asco 2020 – Bavencio “cure” suggests another cancer target for immunotherapy
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
Asco 2020 – Tagrisso shows what early targeting can do
With an 83% reduction in the risk of disease recurrence in early-stage lung cancer, Astrazeneca’s Tagrisso takes the top spot at Asco.
Gilead opts not to buy Arcus
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
US regulator scoops Asco with Bristol’s lung cancer approval
The green light comes two months early, revealing data that were being held back for Asco, but what does Yervoy bring to the table?
